Megan Kelsey
Concepts (320)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 43 | 2026 | 2516 | 4.440 |
Why?
| | Pediatric Obesity | 19 | 2026 | 624 | 4.090 |
Why?
| | Puberty | 12 | 2026 | 140 | 4.010 |
Why?
| | Insulin Resistance | 20 | 2026 | 1232 | 3.540 |
Why?
| | Bariatric Surgery | 10 | 2026 | 236 | 1.800 |
Why?
| | Hypoglycemic Agents | 10 | 2026 | 1379 | 1.560 |
Why?
| | Obesity, Morbid | 9 | 2025 | 275 | 1.420 |
Why?
| | Metformin | 7 | 2023 | 315 | 1.410 |
Why?
| | Adolescent | 68 | 2026 | 22281 | 1.390 |
Why?
| | Obesity | 18 | 2026 | 3057 | 1.310 |
Why?
| | Body Mass Index | 20 | 2026 | 2420 | 1.170 |
Why?
| | Prediabetic State | 6 | 2021 | 243 | 1.130 |
Why?
| | Blood Glucose | 17 | 2026 | 2312 | 1.080 |
Why?
| | Testosterone | 7 | 2024 | 419 | 1.000 |
Why?
| | Hypothalamic Diseases | 2 | 2026 | 17 | 0.970 |
Why?
| | Intra-Abdominal Fat | 2 | 2026 | 100 | 0.930 |
Why?
| | Insulin-Secreting Cells | 3 | 2021 | 387 | 0.920 |
Why?
| | Child | 45 | 2026 | 22537 | 0.860 |
Why?
| | Adolescent Behavior | 3 | 2020 | 500 | 0.850 |
Why?
| | Health Behavior | 3 | 2020 | 782 | 0.820 |
Why?
| | Body Composition | 6 | 2026 | 704 | 0.800 |
Why?
| | Gastrectomy | 4 | 2026 | 157 | 0.770 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.730 |
Why?
| | Transgender Persons | 2 | 2024 | 190 | 0.670 |
Why?
| | Female | 63 | 2026 | 77976 | 0.630 |
Why?
| | Cardiovascular Diseases | 7 | 2023 | 2134 | 0.630 |
Why?
| | Anti-Obesity Agents | 3 | 2026 | 64 | 0.610 |
Why?
| | Humans | 81 | 2026 | 144261 | 0.590 |
Why?
| | Male | 53 | 2026 | 72035 | 0.590 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 13 | 0.560 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 144 | 0.550 |
Why?
| | Insulin | 7 | 2026 | 2501 | 0.550 |
Why?
| | Polycystic Ovary Syndrome | 4 | 2021 | 180 | 0.540 |
Why?
| | Fatty Liver | 3 | 2026 | 251 | 0.530 |
Why?
| | Adipose Tissue | 3 | 2021 | 651 | 0.520 |
Why?
| | Receptor, Melanocortin, Type 4 | 3 | 2026 | 17 | 0.510 |
Why?
| | Body Weight | 1 | 2020 | 976 | 0.480 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1050 | 0.470 |
Why?
| | Glucose Tolerance Test | 6 | 2021 | 360 | 0.470 |
Why?
| | Biomarkers | 5 | 2026 | 4254 | 0.420 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2022 | 3842 | 0.420 |
Why?
| | Depression | 3 | 2024 | 1533 | 0.410 |
Why?
| | Sex Factors | 4 | 2019 | 2096 | 0.410 |
Why?
| | Muscle Fatigue | 1 | 2014 | 97 | 0.390 |
Why?
| | Leptin | 1 | 2015 | 244 | 0.390 |
Why?
| | Muscle, Skeletal | 4 | 2026 | 1792 | 0.380 |
Why?
| | Longitudinal Studies | 6 | 2026 | 2926 | 0.380 |
Why?
| | Task Performance and Analysis | 1 | 2014 | 198 | 0.380 |
Why?
| | Thinness | 1 | 2013 | 99 | 0.380 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 5813 | 0.380 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1318 | 0.370 |
Why?
| | Disease Progression | 1 | 2020 | 2840 | 0.360 |
Why?
| | Off-Label Use | 2 | 2022 | 48 | 0.350 |
Why?
| | Mass Screening | 3 | 2022 | 1332 | 0.340 |
Why?
| | Risk Factors | 9 | 2026 | 10699 | 0.310 |
Why?
| | Life Style | 4 | 2021 | 475 | 0.310 |
Why?
| | Cohort Studies | 8 | 2021 | 5935 | 0.310 |
Why?
| | Metabolic Syndrome | 4 | 2020 | 352 | 0.310 |
Why?
| | Diabetic Nephropathies | 2 | 2026 | 314 | 0.300 |
Why?
| | Androgens | 2 | 2022 | 186 | 0.290 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 51 | 0.290 |
Why?
| | Sleep | 3 | 2024 | 901 | 0.290 |
Why?
| | alpha-MSH | 2 | 2026 | 6 | 0.280 |
Why?
| | Reference Values | 2 | 2020 | 797 | 0.280 |
Why?
| | Ribonuclease III | 2 | 2021 | 44 | 0.270 |
Why?
| | Treatment Outcome | 12 | 2026 | 11643 | 0.260 |
Why?
| | Bone Density | 2 | 2023 | 482 | 0.260 |
Why?
| | Estradiol | 3 | 2022 | 533 | 0.260 |
Why?
| | Weight Gain | 2 | 2022 | 556 | 0.260 |
Why?
| | DEAD-box RNA Helicases | 2 | 2021 | 90 | 0.260 |
Why?
| | Case-Control Studies | 6 | 2021 | 3592 | 0.250 |
Why?
| | Weight Loss | 7 | 2026 | 832 | 0.240 |
Why?
| | Hunger | 1 | 2026 | 57 | 0.240 |
Why?
| | Fructosamine | 2 | 2016 | 11 | 0.240 |
Why?
| | Pituitary Neoplasms | 2 | 2021 | 190 | 0.240 |
Why?
| | Janus Kinases | 1 | 2026 | 20 | 0.230 |
Why?
| | STAT Transcription Factors | 1 | 2026 | 24 | 0.230 |
Why?
| | Adipokines | 1 | 2026 | 57 | 0.230 |
Why?
| | Deoxyglucose | 2 | 2016 | 51 | 0.230 |
Why?
| | Phentermine | 1 | 2025 | 14 | 0.230 |
Why?
| | Diabetes, Gestational | 2 | 2023 | 321 | 0.230 |
Why?
| | Abdominal Fat | 1 | 2025 | 50 | 0.230 |
Why?
| | Serum Albumin | 2 | 2016 | 147 | 0.220 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2026 | 139 | 0.220 |
Why?
| | Young Adult | 11 | 2026 | 13990 | 0.220 |
Why?
| | Heart | 2 | 2025 | 633 | 0.210 |
Why?
| | Follow-Up Studies | 7 | 2023 | 5389 | 0.210 |
Why?
| | Cardiorespiratory Fitness | 1 | 2024 | 72 | 0.210 |
Why?
| | Endocrinology | 1 | 2024 | 75 | 0.200 |
Why?
| | Age Factors | 3 | 2021 | 3313 | 0.200 |
Why?
| | Radius | 2 | 2023 | 52 | 0.200 |
Why?
| | Glucose Clamp Technique | 2 | 2015 | 199 | 0.200 |
Why?
| | Bacteria | 2 | 2020 | 889 | 0.200 |
Why?
| | Hypoglycemia | 2 | 2019 | 477 | 0.190 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 212 | 0.190 |
Why?
| | Aging | 1 | 2014 | 1964 | 0.190 |
Why?
| | Drug Therapy, Combination | 3 | 2025 | 1044 | 0.190 |
Why?
| | Population Health | 1 | 2023 | 44 | 0.190 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 771 | 0.180 |
Why?
| | Double-Blind Method | 3 | 2026 | 2025 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1705 | 0.180 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 172 | 0.180 |
Why?
| | Colorado | 4 | 2020 | 4562 | 0.180 |
Why?
| | Bariatrics | 1 | 2021 | 5 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 5 | 2026 | 3857 | 0.170 |
Why?
| | Obesity Management | 1 | 2021 | 7 | 0.170 |
Why?
| | Hypertension | 2 | 2021 | 1254 | 0.170 |
Why?
| | Mindfulness | 1 | 2024 | 154 | 0.170 |
Why?
| | Overnutrition | 1 | 2021 | 30 | 0.170 |
Why?
| | Blast Crisis | 1 | 2021 | 35 | 0.170 |
Why?
| | Health Status Disparities | 1 | 2024 | 321 | 0.170 |
Why?
| | Adiposity | 2 | 2025 | 541 | 0.160 |
Why?
| | Hyperinsulinism | 1 | 2021 | 113 | 0.160 |
Why?
| | Bone and Bones | 1 | 2023 | 313 | 0.160 |
Why?
| | Bacterial Typing Techniques | 1 | 2020 | 44 | 0.160 |
Why?
| | Time Factors | 4 | 2021 | 7155 | 0.160 |
Why?
| | Hypogonadism | 1 | 2010 | 90 | 0.160 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 75 | 0.150 |
Why?
| | Gastric Bypass | 1 | 2021 | 124 | 0.150 |
Why?
| | Cushing Syndrome | 1 | 2009 | 10 | 0.150 |
Why?
| | Linear Models | 2 | 2019 | 850 | 0.150 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2009 | 12 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1087 | 0.150 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 555 | 0.150 |
Why?
| | Growth Hormone | 1 | 2019 | 92 | 0.150 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 209 | 0.150 |
Why?
| | Sexual Maturation | 1 | 2019 | 51 | 0.150 |
Why?
| | Pseudohypoaldosteronism | 1 | 2009 | 2 | 0.150 |
Why?
| | Prognosis | 4 | 2021 | 4278 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 778 | 0.150 |
Why?
| | Dyslipidemias | 1 | 2021 | 171 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.150 |
Why?
| | Klinefelter Syndrome | 1 | 2020 | 69 | 0.150 |
Why?
| | Research | 1 | 2022 | 428 | 0.150 |
Why?
| | Vascular Malformations | 1 | 2019 | 50 | 0.150 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 114 | 0.140 |
Why?
| | Analysis of Variance | 2 | 2019 | 1304 | 0.140 |
Why?
| | Capillaries | 1 | 2019 | 124 | 0.140 |
Why?
| | Hyperkalemia | 1 | 2009 | 35 | 0.140 |
Why?
| | Reproductive Health | 1 | 2019 | 91 | 0.140 |
Why?
| | Prospective Studies | 5 | 2021 | 7970 | 0.140 |
Why?
| | Obstetric Labor Complications | 1 | 2018 | 37 | 0.140 |
Why?
| | Pilot Projects | 2 | 2024 | 1867 | 0.140 |
Why?
| | Exercise | 3 | 2023 | 2193 | 0.140 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 85 | 0.140 |
Why?
| | Lacerations | 1 | 2018 | 40 | 0.140 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 135 | 0.140 |
Why?
| | Absorptiometry, Photon | 3 | 2026 | 275 | 0.140 |
Why?
| | Exome | 1 | 2019 | 227 | 0.140 |
Why?
| | Psychotherapy, Group | 1 | 2018 | 80 | 0.130 |
Why?
| | Anal Canal | 1 | 2018 | 101 | 0.130 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 225 | 0.130 |
Why?
| | Algorithms | 2 | 2024 | 1834 | 0.130 |
Why?
| | Bacteremia | 1 | 2020 | 221 | 0.130 |
Why?
| | Diet | 2 | 2017 | 1271 | 0.130 |
Why?
| | Delivery, Obstetric | 1 | 2018 | 160 | 0.130 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 379 | 0.130 |
Why?
| | Adenoma | 1 | 2009 | 218 | 0.130 |
Why?
| | Adult | 11 | 2026 | 40262 | 0.130 |
Why?
| | Depressive Disorder | 1 | 2020 | 374 | 0.130 |
Why?
| | C-Peptide | 3 | 2026 | 186 | 0.130 |
Why?
| | Overweight | 1 | 2022 | 606 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2025 | 17009 | 0.120 |
Why?
| | Human Development | 1 | 2016 | 21 | 0.120 |
Why?
| | Hydrocortisone | 1 | 2018 | 304 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2019 | 545 | 0.120 |
Why?
| | Biodiversity | 1 | 2020 | 426 | 0.120 |
Why?
| | Triglycerides | 2 | 2020 | 512 | 0.120 |
Why?
| | Hyperglycemia | 2 | 2016 | 374 | 0.120 |
Why?
| | United States | 8 | 2022 | 15876 | 0.110 |
Why?
| | Risk | 1 | 2017 | 909 | 0.110 |
Why?
| | Adiponectin | 1 | 2016 | 243 | 0.110 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2014 | 7 | 0.110 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2021 | 674 | 0.110 |
Why?
| | Sex Characteristics | 1 | 2019 | 789 | 0.100 |
Why?
| | Patient Education as Topic | 2 | 2018 | 777 | 0.100 |
Why?
| | Lipolysis | 1 | 2013 | 46 | 0.100 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 22 | 0.100 |
Why?
| | Fasting | 1 | 2014 | 276 | 0.100 |
Why?
| | Observer Variation | 1 | 2014 | 354 | 0.100 |
Why?
| | Nutrition Policy | 1 | 2013 | 58 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2013 | 158 | 0.090 |
Why?
| | Feeding Behavior | 1 | 2018 | 681 | 0.090 |
Why?
| | Nutrition Assessment | 1 | 2013 | 92 | 0.090 |
Why?
| | Adolescent Health Services | 1 | 2013 | 75 | 0.090 |
Why?
| | Child, Preschool | 6 | 2026 | 11774 | 0.090 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 180 | 0.090 |
Why?
| | Signal Transduction | 1 | 2026 | 5221 | 0.090 |
Why?
| | Pediatrics | 1 | 2020 | 1112 | 0.090 |
Why?
| | Electromyography | 1 | 2014 | 415 | 0.090 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2011 | 18 | 0.090 |
Why?
| | Physical Fitness | 1 | 2013 | 209 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1092 | 0.090 |
Why?
| | Muscle Contraction | 1 | 2014 | 428 | 0.080 |
Why?
| | Potassium Channels | 1 | 2011 | 145 | 0.080 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 842 | 0.080 |
Why?
| | Pregnancy | 5 | 2023 | 7180 | 0.080 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 265 | 0.080 |
Why?
| | Mutation | 3 | 2019 | 4085 | 0.080 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 1406 | 0.080 |
Why?
| | Tibia | 2 | 2023 | 176 | 0.080 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2014 | 699 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2021 | 2916 | 0.070 |
Why?
| | Motor Activity | 1 | 2013 | 720 | 0.070 |
Why?
| | Peptide YY | 1 | 2026 | 24 | 0.060 |
Why?
| | Hyperpigmentation | 1 | 2026 | 27 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2026 | 164 | 0.060 |
Why?
| | Nausea | 1 | 2026 | 111 | 0.060 |
Why?
| | Vomiting | 1 | 2026 | 130 | 0.060 |
Why?
| | Alanine Transaminase | 1 | 2025 | 151 | 0.060 |
Why?
| | Headache | 1 | 2026 | 150 | 0.060 |
Why?
| | Glycation End Products, Advanced | 2 | 2016 | 82 | 0.060 |
Why?
| | Pro-Opiomelanocortin | 1 | 2024 | 20 | 0.050 |
Why?
| | Hyperphagia | 1 | 2024 | 38 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2026 | 145 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2143 | 0.050 |
Why?
| | Infant | 4 | 2021 | 10022 | 0.050 |
Why?
| | Liver | 2 | 2025 | 1884 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 536 | 0.050 |
Why?
| | Incidence | 2 | 2021 | 2870 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1646 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 402 | 0.050 |
Why?
| | Treatment Failure | 1 | 2023 | 363 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2021 | 2359 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2024 | 724 | 0.040 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2021 | 8 | 0.040 |
Why?
| | Nutrition Disorders | 1 | 2021 | 20 | 0.040 |
Why?
| | Bacteroidetes | 1 | 2021 | 21 | 0.040 |
Why?
| | Transferrin | 1 | 2021 | 50 | 0.040 |
Why?
| | Health Education | 1 | 2024 | 357 | 0.040 |
Why?
| | Animals | 3 | 2019 | 38030 | 0.040 |
Why?
| | Remission Induction | 1 | 2021 | 306 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Blood Culture | 1 | 2020 | 25 | 0.040 |
Why?
| | Waist Circumference | 1 | 2020 | 138 | 0.040 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 143 | 0.040 |
Why?
| | Mice, Obese | 1 | 2009 | 66 | 0.040 |
Why?
| | Fludrocortisone | 1 | 2009 | 2 | 0.040 |
Why?
| | Mineralocorticoids | 1 | 2009 | 7 | 0.040 |
Why?
| | Renin | 1 | 2009 | 34 | 0.040 |
Why?
| | Citrates | 1 | 2009 | 41 | 0.040 |
Why?
| | Epithelial Sodium Channels | 1 | 2009 | 21 | 0.040 |
Why?
| | Aldosterone | 1 | 2009 | 43 | 0.040 |
Why?
| | Dissection | 1 | 2009 | 56 | 0.040 |
Why?
| | Craniotomy | 1 | 2009 | 82 | 0.040 |
Why?
| | Middle Aged | 4 | 2026 | 35762 | 0.040 |
Why?
| | Vitamin D Deficiency | 1 | 2021 | 185 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2009 | 148 | 0.040 |
Why?
| | Episiotomy | 1 | 2018 | 5 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 456 | 0.040 |
Why?
| | Scotland | 1 | 2018 | 23 | 0.040 |
Why?
| | Wales | 1 | 2018 | 26 | 0.040 |
Why?
| | Perineum | 1 | 2018 | 37 | 0.040 |
Why?
| | Potassium | 1 | 2009 | 152 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 558 | 0.030 |
Why?
| | Sodium Chloride | 1 | 2009 | 141 | 0.030 |
Why?
| | Patient Care Bundles | 1 | 2018 | 28 | 0.030 |
Why?
| | England | 1 | 2018 | 111 | 0.030 |
Why?
| | Neoplasms | 1 | 2014 | 2870 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 537 | 0.030 |
Why?
| | Genotype | 1 | 2023 | 1833 | 0.030 |
Why?
| | Genetic Variation | 1 | 2023 | 982 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 481 | 0.030 |
Why?
| | Mitochondria | 1 | 2024 | 983 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2019 | 6424 | 0.030 |
Why?
| | Fecal Incontinence | 1 | 2018 | 91 | 0.030 |
Why?
| | Feces | 1 | 2021 | 513 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 981 | 0.030 |
Why?
| | Physical Examination | 1 | 2018 | 236 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 523 | 0.030 |
Why?
| | Blotting, Western | 1 | 2009 | 1187 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 727 | 0.030 |
Why?
| | Monitoring, Ambulatory | 1 | 2016 | 88 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 329 | 0.030 |
Why?
| | Prenatal Care | 1 | 2018 | 306 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2088 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 758 | 0.030 |
Why?
| | Electrocardiography | 1 | 2009 | 660 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 847 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2019 | 454 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 191 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2009 | 575 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1659 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 6021 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2815 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1682 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 307 | 0.020 |
Why?
| | Aged | 2 | 2026 | 25850 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 405 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 171 | 0.020 |
Why?
| | Pedigree | 1 | 2014 | 513 | 0.020 |
Why?
| | RNA | 1 | 2009 | 939 | 0.020 |
Why?
| | Anthropometry | 1 | 2013 | 199 | 0.020 |
Why?
| | Fruit | 1 | 2013 | 152 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3119 | 0.020 |
Why?
| | Vegetables | 1 | 2013 | 170 | 0.020 |
Why?
| | Mice | 2 | 2019 | 18329 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 97 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2013 | 281 | 0.020 |
Why?
| | Self Concept | 1 | 2013 | 252 | 0.020 |
Why?
| | Dietary Fats | 1 | 2013 | 313 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 380 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 209 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1715 | 0.020 |
Why?
| | Energy Intake | 1 | 2013 | 499 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1285 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1906 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 255 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 730 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3403 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 3166 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 5988 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2111 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8243 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2930 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1401 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2917 | 0.010 |
Why?
| | Lung Diseases | 1 | 2011 | 787 | 0.010 |
Why?
| | Autoantibodies | 1 | 2011 | 1497 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2730 | 0.010 |
Why?
|
|
Kelsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|